Congress forces breakup of pharmacy-insurance monopolies to lower drug costs
S. 4509 — PBM Act · Filed by Elizabeth Warren (D-MA) · 3 cosponsors · Introduced May 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits pharmacy benefit managers (PBMs) and pharmacies from being owned by the same company, and requires companies that currently own both to divest their pharmacy businesses within one year. It empowers the FTC, DOJ, state attorneys general, and private citizens to sue for violations, with penalties including treble damages, profit escrow, and forced divestiture. The stated goal is to eliminate conflicts of interest that allow large health conglomerates to steer patients to their own pharmacies, raising drug costs and closing independent pharmacies.
Why we flagged it
The bill's core mechanism is a structural separation mandate—forcing divestiture of pharmacies from PBM/insurer ownership—rather than a behavioral regulation or price control. This is a classic antitrust remedy targeting vertical integration.
What the text implies
- Divestiture may trigger significant market disruption: large health conglomerates may sell pharmacies to private equity or other acquirers, potentially shifting control to entities with different incentive structures (e.g., cost-cutting over patient access).
- The private right of action with treble damages and attorney's fees creates litigation risk for companies and may generate substantial class-action activity, potentially raising compliance costs industry-wide.
- Profit escrow mechanism (10% monthly) creates a powerful financial incentive for rapid divestiture but may also incentivize fire-sale pricing, potentially harming divested pharmacy viability.
- The bill does not address PBM-insurer integration (only PBM-pharmacy), so the largest conflicts of interest—PBMs steering to their own mail-order and specialty pharmacies while also managing the insurer's drug benefit—remain partially unaddressed.
- State attorneys general parens patriae authority may lead to duplicative enforcement and settlement fragmentation across jurisdictions.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary patients and independent pharmacies gain from reduced steering, lower drug costs, and restored competition. Taxpayers benefit from reduced Medical Loss Ratio gaming. The primary cost falls on large integrated health conglomerates forced to divest, not on citizens.
Who stands to gain
- independent pharmacies (restored competitive position)
- patients (lower drug costs, reduced steering)
- state and federal governments (reduced Medical Loss Ratio gaming, lower Medicaid/Medicare costs)
Named in the bill
Pharmacy Benefit Managers (PBMs), Retail pharmacies, Mail-order pharmacies, Specialty pharmacies, Health insurance companies, Federal Trade Commission (FTC), Department of Justice (DOJ), State Attorneys General, Health and Human Services Inspector General, CVS Health, UnitedHealth Group, Cigna
Where it stands
3 cosponsors: 2 Republicans, 1 Democrats.
- May 13, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- May 13, 2026 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
7 lobbying clients named this bill on 13 disclosure filings across 2 quarters, Jun 2026 to Sep 2026. Those filings disclosed $14,529,039 in lobbying spend. A filing names 34 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 83% of bills with at least one filing.
Elizabeth Warren, the sponsor, reported $18,000 in PAC receipts in the 2026 cycle.
- Pharmaceutical Care Management Association — $6,486,039 on 2 filings
- CVS Health (and Subsidiaries) — $5,610,000 on 2 filings
- National Association of Chain Drug Stores — $770,000 on 2 filings
- Blood Cancer United (fka the Leukemia & Lymphoma Society) — $710,000 on 2 filings
- National Community Pharmacists Association — $640,000 on 2 filings
Lobbying Disclosure Act filings through Oct 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (12,783 characters) on Nov 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 21, 2026 · page rendered 2026-11-22.
“Congress forces breakup of pharmacy-insurance monopolies to lower drug costs” QuorumCivic. https://share.quorumcivic.app/bill/119/s4509 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.